Airway abundance of<i>Haemophilus influenzae</i>predicts response to azithromycin in adults with persistent uncontrolled asthma
Steven Taylor, Kerry L. Ivey, Peter G. Gibson, Jodie L. Simpson, Geraint B. Rogers
Abstract
Long-term azithromycin treatment reduced exacerbations in adults with persistent symptomatic asthma in the AMAZES trial (Australian and New Zealand Clinical Trials Registry (ANZCTR), number 12609000197235) [1]. However, response to treatment was variable between participants and the characteristics of those who experience most clinical benefit have not been determined. The inability to define a specific population who are more responsive limits the ability to personalise this therapy, which is the goal for airways disease management [2]. With recent studies identifying airway Haemophilus influenzae colonisation as a candidate marker for asthma subgrouping [3, 4], we assessed whether H. influenzae abundance, measured using quantitative PCR (qPCR) [5, 6], predicted the ability of azithromycin therapy to reduce the incidence of acute asthma exacerbations. Sputum Haemophilus influenzae load predicts response to azithromycin in adults with persistent uncontrolled asthma: secondary findings from the AMAZES trial <https://bit.ly/3f3tJ71> The following investigators constitute the AMAZES Investigators Group: Ian A. Yang, John W. Upham, Paul N. Reynolds, Sandra Hodge, Alan L. James, Christine Jenkins, Matthew J. Peters, Melissa Baraket and Guy B. Marks.